Paradigm Health and Flatiron Health Join Forces to Enhance Clinical Research Delivery in the U.S.

Paradigm Health and Flatiron Health: Transforming Clinical Research

In a groundbreaking move, Paradigm Health announced its acquisition of Flatiron Health's Clinical Research Business, a pivotal step towards reshaping the clinical research landscape in the United States. This collaboration aims not only to enhance the efficiency of clinical trials but also to ensure that a broader patient population can participate in these life-saving studies.

With this acquisition, Paradigm Health integrates Flatiron's extensive tech-enabled oncology research network, which includes over 25 academic medical centers and nearly 100 community oncology practices across the nation. This expansion allows the companies to reach approximately 2.4 million patients, thereby increasing access to clinical trials—especially for those in rural and underserved communities. The primary goal is to create trials that truly reflect the diverse populations that new therapies are intended to serve.

Kent Thoelke, the CEO of Paradigm Health, emphasized the significance of this partnership, stating, "Clinical research must reflect the populations that new therapies are intended to serve." By leveraging Paradigm's AI-powered platform alongside Flatiron's proven infrastructure, they're set to significantly impact U.S. clinical research. This collaboration aims to conduct more trials in the locales where patients receive their care, thus enhancing the relevance and practicality of the research.

Nathan Hubbard, CEO of Flatiron Health, echoed this sentiment, stating, "This partnership brings together the strengths of both organizations. We're building a stronger, interconnected ecosystem for clinical research that expands our capabilities and accelerates the speed of delivering new treatments to patients."

As part of this strategic partnership, Paradigm Health plans to provide clinical research support to all current Flatiron Health OncoEMR® customers, integrating its solutions seamlessly into Flatiron's existing framework. This integration promises to broaden the range of clinical trial options available to patients, minimizing the infrastructural investments typically required to initiate such studies.

The collaboration is not only about expanding reach but also about improving the quality and efficiency of clinical trials. By implementing AI-driven technologies, the partnership aims to streamline processes, from patient recruitment to data collection and analysis, making trials more accessible and representative of real-world demographics.

Additionally, this synergy between Paradigm Health and Flatiron Health enhances their collective standing in the biopharma sector. With access to 15 of the top 20 global biopharma companies, the combined network is equipped to execute Phase IV clinical trials that can effectively gather evidence in routine clinical settings, which is crucial for post-market approval studies.

This deal represents more than just a business transaction; it signifies a commitment to democratizing access to clinical trials and fostering an inclusive research environment. Both companies share a vision to modernize clinical research and increase participation among diverse patient populations in line with national and global health priorities.

In conclusion, the acquisition of Flatiron's Clinical Research Business by Paradigm Health stands to radically transform clinical research in the oncology space in the U.S. By merging innovative technologies with a vast network of community and academic partners, this partnership is poised to bring crucial therapies to patients more quickly than ever before.

For further information on Paradigm Health and its initiatives, visit Paradigm Health Website.